FDA Approves Tx for Ultra-Rare ALS Condition – Qalsody
This week the FDA approved a new therapy, Qalsody (tofersen) from Biogen MA, Inc., for the treatment of amyotrophic lateral sclerosis (ALS) in adults who
April 28, 2023
This week the FDA approved a new therapy, Qalsody (tofersen) from Biogen MA, Inc., for the treatment of amyotrophic lateral sclerosis (ALS) in adults who
Most would agree that the US has been a litigious-heavy country for decades. As we know, healthcare is one of the biggest targets for lawsuits of
The article below is one that a specialty pharmacy’s legal counsel might find most interesting. In short, the US District Court ruling below said that Humana
The FDA recently approved a therapy previously approved in 2021….. but with a very different indication and a new NDC. The approval was granted for Syfovre
Ever get a letter from more than 400 people? Not 400 letters…. 1 letter with four hundred+ signatories! Over the last week more than 400 of
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
If you have you ever tried to explain all the nuances behind the host of decisions to launch a new specialty therapy through limited distribution, then
Walgreens has tripled down on acquisitions over the past year to the tune of several Billion $$$ in a quest to totally remodel the 122
In the old days (before the internet) the importance of a news item was often expressed in how many column inches the item was generating
We missed one! The FDA recently (back on January 27th) approved a new ORAL therapy, Orserdu (elacestrant) from Stemline Therapeutics, Inc., indicated for postmenopausal women
